Polypeptide related to bacterial envelope inhibition
By developing a polypeptide WK-13-3D with more than 80% identity and antibacterial activity, the problem of inhibiting methicillin-resistant Staphylococcus aureus and its biofilm is solved, and effective inhibition of bacterial growth and biofilm is achieved. A new antibacterial strategy has been developed.
Patent Information
- Application Number
- CN202411056130.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is difficult to effectively inhibit the formation of methicillin-resistant Staphylococcus aureus and its biofilms, resulting in increased treatment difficulty and drug resistance.
A polypeptide was developed to bind to protein tags through substitution, deletion or addition of its amino acid sequence to prepare products that inhibit bacterial growth and biofilms, specifically polypeptide WK-13-3D with an amino acid sequence of WKRIVRRIKRWLR and its derivatives. , has more than 80% identity and antibacterial activity.
This peptide can significantly inhibit the growth and biofilm formation of methicillin-resistant Staphylococcus aureus, providing a new antibacterial strategy with low dose effects and non-toxic side effects.
Smart Images

Figure CN118976095A_ABST
Abstract
Description
Technical Field
[0001] The present invention specifically relates to a polypeptide related to bacterial envelope inhibition. Background Art
[0002] Staphylococcus aureus is a Gram-positive bacterium in the microbiome, widely present in nature, causing countless uncomplicated and invasive infections worldwide each year, and can cause disease by invading the respiratory system, skin mucosa, digestive system, blood system, etc. With the irrational use of antimicrobial drugs, methicillin-resistant Staphylococcus aureus (MRSA) has continued to increase and has shown resistance to multiple antimicrobial drugs, bringing tremendous pressure to clinical anti-infection treatment.
[0003] Biofilm is a bacterial group that is attached to biological or non-biological surfaces and wrapped by its own secreted extracellular polymers to adapt to the living environment. It can protect bacteria from the host immune system attack and antimicrobial killing. The formation of biofilm increases bacterial resistance. Biofilm is the main cause of MRSA-induced diseases, leading to chronic and difficult-to-heal infections. At present, common strategies for treating Staphylococcus aureus biofilm infections include: 1. Phages, using viruses that infect bacteria for treatment, which mainly kill host bacteria during the lysis cycle. To become an anti-biofilm candidate, the following conditions must be met. First, bacteriophages are toxic phages. Studies have shown that mild phages contribute to the horizontal transfer of virulence and antibiotic resistance markers; then phages show a wide host range within their target species; finally, the appropriate phage concentration must be determined for treatment. Evidence shows that low phage doses may promote the development of biofilms in Staphylococcus aureus, which is quite difficult in practical applications. Second, antibodies. Staphylococcus aureus can produce antibodies against a variety of antigens (such as surface proteins, cell wall proteins and toxins) to trigger the natural response of the immune system after infection. Antibodies are highly specific and can avoid damage to the host. However, the antigens expressed by Staphylococcus aureus strains are different. Finding a universal target is one of the challenges currently faced by immunotherapy. Therefore, the development of such a vaccine is very challenging, and antibodies cannot penetrate the deepest layer of the biofilm, so the biofilm will not be completely destroyed. Third, nanotechnology. Research on nanotechnology is currently focused on the use of nanoparticles with antibacterial activity and the development of drug delivery systems. Due to their small molecular weight, they can penetrate biofilms, but there is a lack of research on their interactions and toxicity in the human body and long-term effects. In addition, like traditional antibiotics, there is potential drug resistance. Fourth, traditional Chinese medicine has the characteristics of multiple components, multiple links and multiple targets, and can play a comprehensive advantage in diseases with complex pathologies. In addition to its antibacterial, anti-inflammatory, anti-cancer and vasodilation effects, it also exhibits strong anti-biofilm capabilities. As Girish VM et al. found, however, there are relatively few studies on the effects of traditional Chinese medicine on biofilms, and the depth of the research is relatively shallow. There are few studies on its pathological mechanism and drug mechanism, and different drug concentrations may have a positive correlation with the inhibition of biofilms. 5. Bacteriocins, a naturally occurring peptide with antibacterial properties. They are synthesized by ribosomes of almost all existing bacterial species in order to provide a competitive advantage for niche colonization. Bacteriocins have received increasing attention due to their antibacterial efficacy, ease of manipulation, and their bioengineering to improve target specificity, efficacy, and physical and chemical properties. However, the antibacterial spectrum of bacteriocins is relatively small, and they only work on bacteria that are closely related to the bacteria that produce the bacteriocin, and they have toxic side effects.
[0004] Antimicrobial peptides (AMPs) are a class of small molecule polypeptides widely present in organisms and encoded by specific genes. They have the functions of resisting external microbial invasion and removing mutant cells in the body. They are an important part of the biological natural immune defense system. At present, more than 2,000 antimicrobial peptides have been found to be derived from different species such as bacteria, fungi, mammals, insects, and plants. A large number of studies have confirmed that the antimicrobial mechanism of antimicrobial peptides is different from that of antibiotics. They have the advantages of not being easy to produce drug resistance, no toxic side effects, no residue, and high specificity. At the same time, antimicrobial peptides can be used as adjuvants for traditional antibiotics. Low doses can assist traditional antibiotics in restoring their bactericidal activity against drug-resistant bacteria. How to provide a new antimicrobial peptide is a technical problem faced by people in this field. Summary of the invention
[0005] The technical problem solved by the present invention is how to inhibit bacteria and their biofilms.
[0006] In order to solve the above problems, the present invention provides the following applications.
[0007] The use of a polypeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof, wherein the use is any of the following:
[0008] A1) Application in the preparation of products for inhibiting bacterial growth;
[0009] A2) Use in the preparation of products for inhibiting bacterial biofilm;
[0010] The polypeptide is any one of the following:
[0011] B1), a polypeptide whose amino acid sequence is sequence 1;
[0012] B2), a polypeptide having more than 80% identity with the polypeptide shown in B1) and having the same activity as the polypeptide shown in B1) obtained by substitution and / or deletion and / or addition of amino acid residues of the peptide described in B1);
[0013] B3), a fusion polypeptide obtained by connecting the N-terminus and / or C-terminus of B1) or B2) to a protein tag.
[0014] In the above, the bacteria in A1) may be Gram-positive bacteria. The Gram-positive bacteria may be methicillin-resistant Staphylococcus aureus (MRSA), and the ATCC number of the methicillin-resistant Staphylococcus aureus is ATCC33591.
[0015] In the above polypeptide, the protein tag refers to a polypeptide or protein fused and expressed with the target protein using DNA in vitro recombination technology to facilitate the expression, detection, tracing and / or purification of the target protein. The protein tag can be a Flag tag, a His tag, an MBP tag, an HA tag, a myc tag, a GST tag and / or a SUMO tag, etc.
[0016] In the above, the inhibiting of bacterial biofilm may be inhibiting the growth or formation of bacterial biofilm.
[0017] In the above-mentioned proteins, identity refers to the identity of the amino acid sequence. The identity of the amino acid sequence can be determined using a homology search site on the Internet, such as the BLAST page on the NCBI homepage website. For example, in Advanced BLAST2.1, by using blastp as a program, setting the Expect value to 10, setting all Filters to OFF, using BLOSUM62 as a Matrix, setting the Gap existence cost, Per residue gap cost and Lambda ratio to 11, 1 and 0.85 (default values) respectively, and searching for the identity of a pair of amino acid sequences, the identity value (%) can be obtained.
[0018] In the above proteins, the above 80% identity may be at least 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 95%, 96%, 98%, 99% or 100% identity.
[0019] In the above protein, sequence 1 (SEQ ID No. 1) consists of 13 amino acid residues.
[0020] One or more amino acids of the polypeptide of the present invention can be replaced with amino acids with D-type conformation, artificially modified amino acids, rare amino acids existing in nature, etc., to improve the bioavailability, stability and / or anti-cancer activity of the polypeptide. Among them, D-type amino acids refer to amino acids corresponding to L-type amino acids constituting proteins; artificially modified amino acids refer to common L-type amino acids constituting proteins that have been modified by methylation, phosphorylation, etc.; rare amino acids existing in nature include uncommon amino acids constituting proteins and amino acids that do not constitute proteins, such as 5-hydroxylysine, methylhistidine, γ-aminobutyric acid, homoserine, etc.
[0021] In the above application, the above polypeptide derivative is any one of the following:
[0022] C1) a linker obtained by connecting the amino terminus of the above-mentioned polypeptide to an amino terminus protecting group and / or connecting the carboxyl terminus of the polypeptide according to claim 1 or 2 to a carboxyl terminus protecting group;
[0023] C2) a linker obtained by connecting the carboxyl end of the above polypeptide to an oligopeptide, a lipophilic group or cholesterol;
[0024] C3) a linker obtained by connecting the amino terminus of the above polypeptide to an oligopeptide, a lipophilic group or cholesterol;
[0025] C4) A linker obtained by connecting the amino terminus and the carboxyl terminus of the above-mentioned polypeptide to an oligopeptide or a lipophilic group or cholesterol.
[0026] In the above application, the bacteria is any one of the following:
[0027] H1), bacteria;
[0028] H2), Gram-negative bacteria.
[0029] In order to solve the above problems, the present invention also provides a biomaterial.
[0030] The biological material is any of the following:
[0031] B1), a nucleic acid molecule encoding the above peptide;
[0032] B2), an expression cassette containing the nucleic acid molecule described in B1);
[0033] B3), a recombinant vector containing the nucleic acid molecule described in B1), or a recombinant vector containing the expression cassette described in B2);
[0034] B4), a recombinant cell containing the nucleic acid molecule described in B1), or a recombinant cell containing the expression cassette described in B2), or a recombinant cell containing the recombinant vector described in B3);
[0035] B5), a recombinant tissue containing the nucleic acid molecule described in B1), or a recombinant tissue containing the expression cassette described in B2), or a recombinant tissue containing the recombinant vector described in B3);
[0036] B6), a recombinant organ containing the nucleic acid molecule described in B1), or a recombinant organ containing the expression cassette described in B2), or a recombinant organ containing the recombinant vector described in B3);
[0037] B7), a recombinant individual containing the nucleic acid molecule described in B1), or a recombinant individual containing the expression cassette described in B2), or a recombinant individual containing the recombinant vector described in B3).
[0038] B8), a recombinant microorganism containing the nucleic acid molecule described in B1), or a recombinant microorganism containing the expression cassette described in B2), or a recombinant microorganism containing the recombinant vector described in B3).
[0039] B1) In the nucleic acid molecule, a person skilled in the art can easily mutate the nucleotide sequence encoding the above polypeptide of the present invention by using known methods, such as directed evolution or point mutation. Those artificially modified nucleotides having 80% or more identity with the nucleotide sequence of the polypeptide isolated from the present invention are derived from the nucleotide sequence of the present invention and are equivalent to the sequence of the present invention as long as they encode the polypeptide and have the ability to inhibit the growth of cancer cells.
[0040] The above 80% or more identity may be 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity.
[0041] Herein, identity refers to the identity of an amino acid sequence or a nucleotide sequence. The identity of an amino acid sequence can be determined using a homology search site on the Internet, such as the BLAST webpage on the NCBI homepage website. For example, in Advanced BLAST2.1, by using blastp as a program, setting the Expect value to 10, setting all Filters to OFF, using BLOSUM62 as a Matrix, setting Gap existence cost, Per residue gap cost and Lambda ratio to 11, 1 and 0.85 (default values) respectively and searching to calculate the identity of an amino acid sequence, the value (%) of identity can then be obtained.
[0042] In the above biological material, the nucleic acid molecule in B1) may be a gene encoding the protein. Specifically, the nucleic acid molecule in B1) may be a DNA molecule whose coding sequence of the coding chain is shown in Sequence 1.
[0043] Herein, the vector is well known to those skilled in the art, including but not limited to: plasmid, phage (such as lambda phage or M13 filamentous phage, etc.), cosmid (ie, cosmid), Ti plasmid or viral vector.
[0044] In the above biological materials, the expression cassette described in B2) refers to a DNA capable of expressing the gene in a host cell, and the DNA may include not only a promoter for initiating gene transcription, but also a terminator for terminating gene transcription. Furthermore, the expression cassette may also include an enhancer sequence.
[0045] In the above-mentioned application of biomaterials, the application is any one of the following:
[0046] A1) Application in the preparation of products for inhibiting bacterial growth;
[0047] A2) Application in the preparation of products for inhibiting bacterial biofilm.
[0048] In order to solve the above problems, the present invention also provides a composition.
[0049] The composition comprises the above-mentioned polypeptide, its derivative, or its pharmaceutically acceptable salt;
[0050] The composition has at least one of the following functions:
[0051] E1) inhibits bacterial growth;
[0052] E2) in inhibiting bacterial biofilm.
[0053] In the above composition, the bacteria is any one of the following:
[0054] H1), bacteria;
[0055] H2), methicillin-resistant Staphylococcus aureus.
[0056] In order to solve the above problems, the present invention also provides the following application.
[0057] The application of the above-mentioned composition is any of the following:
[0058] A1) Use in the preparation of products for inhibiting bacterial growth;
[0059] A2) Use in the preparation of products for inhibiting bacterial biofilm formation.
[0060] In the above application or the above composition, the product may be a medicine.
[0061] In the above, the composition or medicine further includes a pharmaceutically acceptable carrier or excipient.
[0062] In practical applications, the polypeptides, pharmaceutical salts thereof, derivatives thereof, polymers and compositions of the present invention can be directly administered to patients as drugs, or can be administered to patients after being mixed with suitable carriers or excipients. The carrier materials here include, but are not limited to, water-soluble carrier materials (such as polyethylene glycol, polyvinyl pyrrolidone, organic acids, etc.), poorly soluble carrier materials (such as ethyl cellulose, cholesterol stearate, etc.), and enteric carrier materials (such as cellulose acetate phthalate and carboxymethyl ethyl cellulose, etc.). Among them, water-soluble carrier materials are preferred. These materials can be made into a variety of dosage forms, including but not limited to tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, freeze-dried powder injections, etc. It can be a common preparation, a sustained-release preparation, a controlled-release preparation and various microparticle delivery systems. In order to make a unit dosage form into a tablet, various carriers known in the art can be widely used. Examples of carriers include diluents and absorbents, such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate, etc.; wetting agents and binders, such as water, glycerol, polyethylene glycol, ethanol, propanol, starch paste, dextrin, syrup, honey, glucose solution, acacia paste, gelatin paste, sodium carboxymethylcellulose, shellac, methylcellulose, potassium phosphate, polyvinyl pyrrolidone, etc.; disintegrants. , such as dry starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitan fatty acid esters, sodium lauryl sulfate, methyl cellulose, ethyl cellulose, etc.; disintegration inhibitors, such as sucrose, tristearate, cocoa butter, hydrogenated oil, etc.; absorption promoters, such as quaternary ammonium salts, sodium lauryl sulfate, etc.; lubricants, such as talc, silicon dioxide, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, etc. The tablets can also be further made into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer tablets and multi-layer tablets. In order to make the unit dosage form into a pill, various carriers known in the art can be widely used. Examples of carriers include diluents and absorbents, such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, polyvinyl pyrrolidone, Gelucire, kaolin, talc, etc.; binders, such as gum arabic, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or flour paste, etc.; disintegrants, such as agar powder, dry starch, alginate, sodium lauryl sulfate, methyl cellulose, ethyl cellulose, etc. In order to prepare a unit dosage form as a suppository, various carriers known in the art can be widely used. Examples of carriers include, for example, polyethylene glycol, lecithin, cocoa butter, higher alcohols, esters of higher alcohols, gelatin, semi-synthetic glycerides, etc.In order to prepare the unit dosage form into an injectable preparation, such as a solution, emulsion, freeze-dried powder injection and suspension, all diluents commonly used in the art can be used, for example, water, ethanol, polyethylene glycol, 1,3-propylene glycol, ethoxylated isostearyl alcohol, polyoxygenated isostearyl alcohol, polyoxyethylene sorbitol fatty acid esters, etc. In addition, in order to prepare an isotonic injection, an appropriate amount of sodium chloride, glucose or glycerol can be added to the injectable preparation. In addition, conventional cosolvents, buffers, pH regulators, etc. can also be added. In addition, if necessary, colorants, preservatives, spices, flavoring agents, sweeteners or other materials can also be added to the pharmaceutical preparation. The above dosage form can be used for administration by injection, including subcutaneous injection, intravenous injection, intramuscular injection and intracavitary injection, etc.; cavity administration, such as rectal and vaginal; respiratory tract administration, such as nasal; mucosal administration. The above administration route is preferably injection.
[0063] In order to solve the above problems, the present invention also provides a polypeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof.
[0064] The polypeptide is any one of the following:
[0065] B1), a polypeptide whose amino acid sequence is sequence 1;
[0066] B2), a polypeptide having more than 80% identity with the polypeptide shown in B1) and having the same activity as the polypeptide shown in B1) obtained by substitution and / or deletion and / or addition of amino acid residues of the peptide described in B1);
[0067] B3), a fusion polypeptide obtained by connecting the N-terminus and / or C-terminus of B1) or B2) to a protein tag.
[0068] In order to solve the above problems, the present invention also provides a composition.
[0069] The composition comprises the above polypeptide, its derivative, or its pharmaceutically acceptable salt.
[0070] Beneficial Effects
[0071] The present invention discloses a polypeptide related to bacterial membrane inhibition. The technical problem to be solved is how to inhibit bacteria and their biofilms, especially methicillin-resistant Staphylococcus aureus. Specifically disclosed are the applications of polypeptides, pharmaceutical salts thereof, or derivatives thereof. The applications are any of the following: A1) application in the preparation of products for inhibiting bacterial growth; A2) application in the preparation of products for inhibiting bacterial biofilms; the polypeptide is any of the following: B1), a polypeptide whose amino acid sequence is sequence 1; B2), a polypeptide having more than 80% identity and the same activity as the polypeptide shown in B1) obtained by replacing and / or deleting and / or adding amino acid residues of the peptide described in B1); B3), a fusion polypeptide obtained by connecting the N-terminus or / and C-terminus of B1) or B2) to a protein tag. The above-mentioned polypeptides, pharmaceutical salts thereof, or derivatives thereof are applied to methicillin-resistant Staphylococcus aureus to inhibit its and biofilm growth. It can be used for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0072] Figure 1 This is the biofilm inhibition diagram of WK-13-3D; Figure 1 Middle A: MRSA biofilm inhibition test measured absorbance at 600 nm; Figure 1 Middle B: MRSA biofilm inhibition rate. DETAILED DESCRIPTION
[0073] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0074] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0075] The following examples used GraphPad statistical software to process the data, and the experimental results were expressed as mean ± standard deviation. One-way ANOVA test was used, and P < 0.05 (*) indicated a significant difference, P < 0.01 (**) indicated a very significant difference, and P < 0.001 (***) indicated a very significant difference.
[0076] Experimental Materials:
[0077] Methicillin-resistant Staphylococcus aureus (MRSA) (ATCC Product Name of MRSA is ATCC33591) was provided by the Key Laboratory of Pathogenic Microorganisms of Ningxia Medical University.
[0078] 1% glucose in TBS liquid culture medium: weigh 6.0 g of TBS powder and 0.2 g of glucose, dissolve in 150 mL of ultrapure water, then adjust the pH value to 7.0, continue to add ultrapure water to a final volume of 200 mL, sterilize with high-pressure steam at 121°C for 20 min, and store in a 4°C refrigerator for later use.
[0079] 1% glucose TBS solid culture medium: weigh 6.0 g TBS powder, 0.2 g glucose, and 4 g agar, dissolve in 150 mL ultrapure water, then adjust the pH value to 7.0, continue to add ultrapure water to make the final volume 200 mL, sterilize with high-pressure steam at 121°C for 20 min, and store in a 4°C refrigerator for later use.
[0080] PBS was purchased from Hyclone Company / USA, catalog number SH30256.01.
[0081] Crystal violet was purchased from Beyotime Corporation / China.
[0082] Glacial acetic acid was purchased from Tianjin Damao Chemical Reagent Factory / China.
[0083] The amino acid sequence of the antimicrobial peptide WK-13-3D is WKRIVRRIKRWLR (sequence 1). The carbon terminal of the antimicrobial peptide WK-13-3D is amidated, and the nitrogen terminal is not treated. It was synthesized by Gill Biochemical (Shanghai) Co., Ltd.
[0084] Preparation of antimicrobial peptide WK-13-3D solution: dissolve the antimicrobial peptide WK-13-3D in deionized water to make the concentration of the antimicrobial peptide WK-13-3D 64 μmol / L to obtain the antimicrobial peptide WK-13-3D solution.
[0085] Example 1 MIC determination of MRSA
[0086] The antimicrobial peptide WK-13-3D solution was diluted with deionized water so that the concentrations of the antimicrobial peptide WK-13-3D were 0, 2, 4, 8, 16, 32, and 64 μmol / L, respectively, to obtain 0 μmol / L antimicrobial peptide WK-13-3D solution, 2 μmol / L antimicrobial peptide WK-13-3D solution, 4 μmol / L antimicrobial peptide WK-13-3D solution, 8 μmol / L antimicrobial peptide WK-13-3D solution, 16 μmol / L antimicrobial peptide WK-13-3D solution, 32 μmol / L antimicrobial peptide WK-13-3D solution, and 64 μmol / L antimicrobial peptide WK-13-3D solution, respectively.
[0087] 1. A single colony of methicillin-resistant Staphylococcus aureus (MRSA) was inoculated into TBS liquid medium containing 1% glucose and cultured overnight at 37°C and 180 r / min to obtain overnight culture solution. 500 μL of the overnight culture solution was added to 10 mL of TBS liquid medium containing glucose and cultured for 2 h (37°C, 180 r / min). OD 600 Adjust the concentration of the bacterial solution to 0.5 McFarland turbidity and dilute it 1000 times with 1% glucose in TBS liquid medium to a bacterial concentration of 1×10 5 CFU / mL, and obtain methicillin-resistant Staphylococcus aureus liquid.
[0088] 2. Add 100 μL of 2 μmol / L antimicrobial peptide WK-13-3D solution, 100 μL of 4 μmol / L antimicrobial peptide WK-13-3D solution, 100 μL of 8 μmol / L antimicrobial peptide WK-13-3D solution, 100 μL of 16 μmol / L antimicrobial peptide WK-13-3D solution, 100 μL of 32 μmol / L antimicrobial peptide WK-13-3D solution and 100 μL of 64 μmol / L antimicrobial peptide WK-13-3D solution to the 96-well culture plate, and then add 100 μL of the above-mentioned methicillin-resistant Staphylococcus aureus bacterial solution, the final volume is 200 μL, and three replicates are performed in each group. 1% glucose TBS liquid medium is used as a negative control, and 100 μL of deionized water is added to 100 μL of 1% glucose TBS liquid medium as a positive control.
[0089] 3. Incubate at 37℃ for 24h, and measure the absorbance at 600nm with a microplate reader. The maximum concentration at which the OD value no longer changes significantly is defined as the minimum inhibitory concentration (MIC). The results are shown in Table 1, and the minimum inhibitory concentration (MIC) is 8μmol / L.
[0090] Table 1 MIC determination of MRSA
[0091]
[0092] Example 2 Biofilm formation inhibition experiment
[0093] 0.1% Crystal Violet: 0.5 g of solid crystal violet powder was dissolved in 50 mL of methanol.
[0094] 33% glacial acetic acid: dilute 5 mL of glacial acetic acid to 100 mL with water.
[0095] 1. A single colony of methicillin-resistant Staphylococcus aureus (MRSA) was inoculated in TBS liquid medium containing 1% glucose and cultured overnight at 37°C and 180 r / min. 1% of the bacterial solution was taken and continued to be amplified for 2 hours. The concentration of the bacterial solution was adjusted to 0.5 McFarland turbidity by OD600 and diluted 100 times with TBS liquid medium containing 1% glucose to a bacterial concentration of 1×10 6 CFU / mL, and dispense 100 μL of the diluted bacterial solution into a 96-well culture plate.
[0096] 2. 16 μmol / L antimicrobial peptide WK-13-3D solution, 8 μmol / L antimicrobial peptide WK-13-3D solution and 100 μL of 4 μmol / L antimicrobial peptide WK-13-3D solution were added to the 96-well culture plate prepared above, so that the final concentrations of antimicrobial peptide WK-13-3D were MIC, 1 / 2MIC, and 1 / 4MIC, respectively. 1% glucose in TBS liquid culture medium was used as a negative control, and 100 μL of the above 100 μL bacterial solution was added to 100 μL of 1% glucose in TBS liquid culture medium as a positive control. The plates were incubated at 37°C for 24 h. Each concentration drug treatment group had 4 replicate wells.
[0097] 3. After the culture is completed, the culture medium is gently removed by aspiration, and the cells are repeatedly washed with PBS for 3 times to remove floating bacteria and impurities. Then, 200 μL of methanol is added to each well to fix the biofilm. After 15 minutes, the methanol is removed, and after drying, 200 μL of 0.1% crystal violet is added to stain for 10 minutes. Then, the excess stain is washed away, and the cells are dried. 200 μL of 33% glacial acetic acid is added to each well. After high-speed oscillation of the microplate reader for 20 minutes, the absorbance at a wavelength of 600 nm is measured. The inhibition rate is calculated according to the formula: inhibition rate = [(A 处理 -A 阴 ) / (A0-A 阴 )] × 100%. The results are shown in Table 2 and Figure 1 As shown ( Figure 1 A is the absorbance graph measured at 600 nm, and 0, 2, 4, and 8 correspond to different concentrations of antimicrobial peptide WK-13-3D (μmol / L). Figure 1 B is the general Figure 1 The result of converting the A parameter into inhibition rate is shown in the figure. 0, 2, 4 and 8 correspond to different concentrations of antimicrobial peptide WK-13-3D (μmol / L). (A0 represents the absorbance of the positive control at 600nm, A 阴represents the absorbance of negative control at 600nm, A 处理 It indicates that 2, 4, and 8 different concentrations of antimicrobial peptide WK-13-3D were added and the absorbance of bacteria at 600nm was also added).
[0098] Table 2 MRSA bioassay
[0099]
[0100] The experimental results showed that the minimum inhibitory concentration of antimicrobial peptide WK-13-3D against MRSA was 8μmol / L. After the antimicrobial peptide WK-13-3D with different concentrations of MIC (8μmol / L), 1 / 2MIC (4μmol / L), and 1 / 4MIC (2μmol / L) acted on MRSA, the bacterial biofilm could be significantly inhibited, and it was concentration-dependent. The results showed that the antimicrobial peptide WK-13-3D could significantly inhibit the formation of MRSA biofilm.
[0101] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.
Claims
1. Use of a polypeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof, characterized in that: The application is any of the following: A1) Application in the preparation of products for inhibiting bacterial growth; A2) Use in the preparation of products for inhibiting bacterial biofilm; The polypeptide is any one of the following: B1), a polypeptide whose amino acid sequence is sequence 1; B2), a polypeptide having more than 80% identity with the polypeptide shown in B1) and having the same activity as the polypeptide shown in B1) obtained by substitution and / or deletion and / or addition of amino acid residues of the peptide described in B1); B3), a fusion polypeptide obtained by connecting the N-terminus and / or C-terminus of B1) or B2) to a protein tag.
2. The use according to claim 1, characterized in that: The polypeptide derivative according to claim 1 is any one of the following: C1) a linker obtained by connecting the amino terminus of the polypeptide of claim 1 to an amino terminus protecting group and / or connecting the carboxyl terminus of the polypeptide of claim 1 or 2 to a carboxyl terminus protecting group; C2) a linker obtained by connecting the carboxyl end of the polypeptide according to claim 1 to an oligopeptide, a lipophilic group or cholesterol; C3) a linker obtained by connecting an oligopeptide, a lipophilic group or cholesterol to the amino terminus of the polypeptide of claim 1; C4) A linker obtained by connecting the amino terminus and the carboxyl terminus of the polypeptide according to claim 1 to an oligopeptide, a lipophilic group or cholesterol.
3. The use according to claim 1 or 2, characterized in that: The bacteria is any of the following: H1), bacteria; H2), Gram-negative bacteria.
4. Biomaterial, characterized in that The biological material is any of the following: B1), a nucleic acid molecule encoding the peptide according to claim 1; B2), an expression cassette containing the nucleic acid molecule described in B1); B3), a recombinant vector containing the nucleic acid molecule described in B1), or a recombinant vector containing the expression cassette described in B2); B4), a recombinant cell containing the nucleic acid molecule described in B1), or a recombinant cell containing the expression cassette described in B2), or a recombinant cell containing the recombinant vector described in B3); B5), a recombinant tissue containing the nucleic acid molecule described in B1), or a recombinant tissue containing the expression cassette described in B2), or a recombinant tissue containing the recombinant vector described in B3); B6), a recombinant organ containing the nucleic acid molecule described in B1), or a recombinant organ containing the expression cassette described in B2), or a recombinant organ containing the recombinant vector described in B3); B7), a recombinant individual containing the nucleic acid molecule described in B1), or a recombinant individual containing the expression cassette described in B2), or a recombinant individual containing the recombinant vector described in B3). B8), a recombinant microorganism containing the nucleic acid molecule described in B1), or a recombinant microorganism containing the expression cassette described in B2), or a recombinant microorganism containing the recombinant vector described in B3).
5. The use of the biomaterial according to claim 4, characterized in that: The application is any of the following: A1) Application in the preparation of products for inhibiting bacterial growth; A2) Application in the preparation of products for inhibiting bacterial biofilm.
6. A composition, characterized in that The composition comprises the polypeptide according to claim 1, its derivative, or its pharmaceutically acceptable salt; The composition has at least one of the following functions: E1) inhibits bacterial growth; E2) in inhibiting bacterial biofilm.
7. The use of the composition according to claim 7, characterized in that: The application is any of the following: A1) Use in the preparation of products for inhibiting bacterial growth; A2) Use in the preparation of products for inhibiting bacterial biofilm formation.
8. The use according to claim 1-3, 5 or 7 or the composition according to claim 6, characterized in that The product may be a pharmaceutical.
9. A polypeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof, characterized in that: The polypeptide is any one of the following: B1), a polypeptide whose amino acid sequence is sequence 1; B2), a polypeptide having more than 80% identity with the polypeptide shown in B1) and having the same activity as the polypeptide shown in B1) obtained by substitution and / or deletion and / or addition of amino acid residues of the peptide described in B1); B3), a fusion polypeptide obtained by connecting the N-terminus and / or C-terminus of B1) or B2) to a protein tag.
10. A composition, characterized in that The composition comprises the polypeptide according to claim 1, its derivative, or its pharmaceutically acceptable salt.
Citation Information
Cited By
Application of antibacterial peptide WK-13-3D in preparation of drugs for inhibiting Japanese encephalitis virus infection
CN119950676A
